anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Patients with glioma who are positive for the H3 K27M mutation (positive testing in CLIA laboratory) or have diagnosed diffuse intrinsic pontine glioma (DIPG), defined as tumors with a pontine epicenter and diffuse involvement of the pons, are eligible with or without histologic confirmation. Patients must be 2-12 weeks from completion of first-line radiation.
The present disclosure relates to a gastric residence article for oral administration. The article comprises a foldable central component, a plurality of elongated limb components and a plurality of linker components. The foldable central component comprises a plurality of ribs that include at least one superelastic alloy. The elongated limb components are radially attached to the foldable central component, wherein the plurality of elongated limb components correspond to the plurality of ribs. Each of the linker components connects one of the elongated limb components to the foldable central component. The ribs are releasable from a folded first state to an unfolded second state for deploying the elongated limb components. At least one of the elongated limb components is configured to releasably store drugs. The linker components are configured to transform from a rigid first state to a disengaged second state to allow the elongated limb component to move independently with respect to the foldable central component.
1361574 4-(4-Biphenylyl)-1-butanol; biphenylyl intermediates DR KARL THOMAE GmbH 13 Oct 1972 [15 Oct 1971] 47442/72 Heading C2C The invention comprises 4-(4-biphenylyl)-1- butanol. It may be prepared by the following methods: (a) reduction of a compound of Formula II in which B represents a hydroxy, alkoxy, aralkoxy, aryloxy or acyloxy group or a halogen atom, e.g. by a complex hydride or catalytically activated hydrogen or if B is halogen by sodium borohydride; (b) reduction of a compound of Formula II above or a compound of Formula III in which A is a hydroxymethylene or keto group, Y and Z are hydrogen or together represent a double bond and B<SP>1</SP> represents a hydroxyalkoxy, aralkoxy or aryloxy group or (if A is a keto group) an acyloxy group or (if A is a keto group and Y and Z represent a double bond) a halogen atom by hydrogenation in the presence of a catalyst, e.g. copper chromium oxide or zinc chromium oxide, (c) from compounds of Formula IV or Formula IVa by hydrogenation in the presence of a catalyst, e.g. noble metal catalysts, copper chromium oxide or zinc chromium oxide; (d) reaction of a Grignard reagent of Formula V with ethylene oxide; (e) hydrogenation of 4-(4- biphenylyl)-3-buten-1-ol in the presence of a catalyst, e.g. Raney nickel or Raney cobalt; (f) treatment of 3-(4-biphenylyl)<SP>1</SP>-tetrohydrofuran with hydrogen in the presence of an acid and a catalyst, e.g. palladium on charcoal. The 1-(4-biphenylyl)-1,4-butanediol used as starting material in method (c) above may be prepared by reacting biphenyl with ethylene oxide in the presence of aluminium chloride to give 4-(4- biphenylyl)-4-oxo-butyric acid which is then treated with lithium aluminium hydride to give the required compound. 4-(4-Biphenylyl)-1-butanol is used as the active ingredient in pharmaceutical compositions which may also contain conventional diluents and extenders and may be administered in the form of tablets, pills, gelatin capsules or suppositories.
[GB1361574A]
Pyroptosis is one kind of programmed cell death in which the cell membrane ruptures and subsequently releases cell contents and pro-inflammatory cytokines including IL-1β and IL-18. Pyroptosis is caused by many types of pathological stimuli, such as hyperglycemia (HG), oxidative stress, and inflammation, and is mediated by gasdermin (GSDM) protein family. Increasing evidence indicates that pyroptosis plays an important role in multiple diseases, such as cancer, kidney diseases, inflammatory diseases, and cardiovascular diseases. Therefore, the regulation of pyroptosis is crucial for the occurrence, development, and treatment of many diseases. Hydrogen sulfide (H2S) is a biologically active gasotransmitter following carbon monoxide (CO) and nitrogen oxide (NO) in mammalian tissues. So far, three enzymes, including 3-mercaptopyruvate sulphurtransferase (3-MST), cystathionine γ- Lyase (CSE), and Cystine β-synthesis enzyme (CBS), have been found to catalyze the production of endogenous H2S in mammals. H2S has been reported to have multiple biological functions including anti-inflammation, anti-oxidative stress, anti-apoptosis and so on. Hence, H2S is involved in various physiological and pathological processes. In recent years, many studies have demonstrated that H2S plays a critical role by regulating pyroptosis in various pathological processes, such as ischemia-reperfusion injury, alcoholic liver disease, and diabetes cardiomyopathy. However, the relevant mechanism has not been completely understood. Therefore, elucidating the mechanism by which H2S regulates pyroptosis in diseases will help understand the pathogenesis of multiple diseases and provide important new avenues for the treatment of many diseases. Here, we reviewed the progress of H2S regulation of pyroptosis in different pathological processes, and analyzed the molecular mechanism in detail to provide a theoretical reference for future related research.
PROBLEM TO BE SOLVED: To obtain a composition for oral cavity, having a grain size of capsules specified by using agar as a substance for forming the tunica of the capsules, capable of easily breaking by brushing and greatly reducing a sandy feeling arising from the capsules in its using. SOLUTION: This composition contains the following (a) and (b) components besides (c)-(e) components. (a) capsules containing 0.1-20wt.% of agar as a substance for forming its a tunica and having an average grain size of 0.3-3mm, (b) 0.0001-1% of more than one kinds of perfumes selected from linalol, eugenol, anethole, terpineol, thymol, camphor, cinnamic alcohol, cinnamic aldehyde and cineol, (c) 0.1-1% of menthol, (d) a nonicnic surfactant (e.g. polyoxyethylene-poly- oxypropylene block copolymer), (e) an abrasive (e.g. calcium carbonate). It is possible to prepare in the dosage forms of tooth paste, tooth powder, tooth liquid, mouth rinse, gum massage cream, etc.
Arsenic, an environmental pollutant and poisonous metalloid, has adverse effects on different body organs, including the kidneys. Betaine is a natural nutrient that has many beneficial health effects. This research was conducted to examine the impact of betaine on nephrotoxicity caused by inorganic arsenic (NaAsO2) in mice. Mice were separated into following groups: control, NaAsO2 (50 ppm), NaAsO2 (50 ppm) + betaine (500 mg/kg), and betaine (500 mg/kg). Mice were received NaAsO2 via drinking water for 8 consecutive weeks and betaine was given to the animals via gavage once daily in the 7th and 8th weeks of the study. Upon completion of the study, the mice were euthanized and samples of serum and kidney were obtained for further evaluations. Administration of NaAsO2 increased the levels of blood urea nitrogen and creatinine in the serum. It enhanced the amounts of renal malondialdehyde and decreased the total thiol levels, as well as the activity of antioxidant enzymes (catalase, superoxide dismutase, and glutathione peroxidase). Furthermore, it enhanced the levels of renal inflammatory indicators (tumor necrosis factor-alpha and nitric oxide). Western blot results exhibited an increase in the protein expression of nuclear factor kappa B (NF-κB), and phosphorylated NF-κB in NaAsO2-treated mice. Histopathological results also confirmed kidney damage caused by NaAsO2. However, treatment with betaine improved NaAsO2-related kidney injuries in mice. The results of this work indicated that betaine can attenuate kidney damage caused by NaAsO2 by inhibiting oxidative stress and inflammation.
5,8-Dimethyltocol, 7,8-dimethyltocol, 8-methyltocol, 5-methyltocol, 5,7-dimethyltocol and 7-methyltocol are converted into products of enhanced Vitamin E activity, particularly 5,7,8-trimethyltocol by a process wherein one or more of the hydrogen atoms in the 5,7 and 8-positions of said tocol, or an ester or ether thereof, is replaced by an alkyl, aryl or aralkyl group, by reacting the tocol or ester or ether thereof with an aldehyde of the general formula R.CHO, where R is a hydrogen atom or an alkyl, aryl or aralkyl group in the presence of a compound of one of the general formula PX5, POX3, SO2X2 or XSO3H, where X is chlorine or bromine to give a compound or compounds containing substituted alkyl, aryl or aralkyl groups capable of conversion to alkyl, aryl or aralkyl groups and then converting said groups to alkyl, aryl or aralkyl groups.  Compounds of the above general formul  are phosphorus pentachloride, phosphorus oxychloride, sulphuryl chloride, chlorosulphonic acid and the analogous bromine compounds.  The intermediate 5,7,8-substituted alkyl, aryl, or aralkyl tocols are converted to the corresponding 5,7 and/or 8-alkyl, aryl or aralkyl tocols by hydrolysis and reduction, or by reduction alone, e.g. the Clemmensen reduction or catalytic hydrogenation.  For the production of a -tocopherol, paraformaldehyde or dry formaldehyde gas may be employed.  Examples use as starting materials 7,8-dimethyltocol, 5,7-dimethyltocol, rice oil concentrate, and soybean oil concentrate; the halogenating agents indicated above are also used.  Specifications 629,649, 639,011, 676,853, 681,507 and 681,508 are referred to.
Disclosed herein are systems, methods and devices for predicting whether a user has a target health condition using eye images. Automated guidance is provided to the user to obtain, using a computing device operated by the user, images including the user's sclera, each of the images corresponding to a guided direction of the user's gaze. Images are received from the computing device by way of a network. Images are subject to verification that sufficiently show the user's sclera, including by estimating a direction of the user's gaze and confirming that the estimated direction for a given one of the images conforms with the guided direction. Feature-enhanced image data are generated by applying an autoencoder to enhance features corresponding to the user's sclera in the images. A prediction of whether the user has the target health condition is generated by providing the feature-enhanced image data to a convolutional neural network.
Disclosed herein are methods of inhibiting sperm motility. In some embodiments, a method of inhibiting sperm motility includes contacting a sperm with an effective amount of 3BP, thereby inhibiting sperm motility. Also disclosed herein are methods of contraception. In some embodiments, a method of contraception includes administering an effective amount of 3BP to the vagina so that sperm in contact with 3BP change their swimming patterns, which are incompatible with fertilization, thus preventing pregnancy. In one embodiment, a method includes topical application of 3BP to the penis in an amount effective to cause complete loss of motility of ejaculated sperm during sexual intercourse, thereby achieving contraception. In some examples, 3BP is administered as a spermicide in the forms of a jelly (gel), films, sponges, foams and timed-release mesh. In some examples, condoms are coated with 3BP-containing lubricant to achieve contraception.
PROBLEM TO BE SOLVED: To obtain a new xanthone derivative having an antitumor activity against solid tumors in vivo, stable in vivo, and useful as an active ingredient for antitumor medicines. SOLUTION: This xanthone derivative is a compound of the formula (R<1> amino, a 1-8C linear, branched or cyclic alkylamino; R<2> , R<3> are each H, a 1-8C linear or branched acyl, a 1-8C linear or branched alkyl), e.g. a compound of formula II. The compound of formula I is obtained by subjecting an antibiotic F390 of formula III as a raw material to reactions such as a reduction reaction and an alkali hydrolysis reaction. The antibiotic F390 can be obtained by culturing Penicillium sp. AJ117292) and then collecting the antibiotic from the culture product.
Thoracolumbar interfacial plane (TLIP) Block will be performed after induction of anesthesia by anesthesiologist who is not part of investigators for this study. Bilateral 20 ml 0.25 % Bupivacaine injected between multifidus and longissimus muscle with Ultrasound guidance.
Ferric citrate will be taken with or within one hour of meals or snacks. The starting dose of ferric citrate is 3 tablets/day and titrated by the subject's serum phosphorus results at each treatment visit.
BACKGROUND: Digestive system cancers represent a significant global health challenge and are attributed to a combination of demographic and lifestyle changes. Lipidomics has emerged as a pivotal area in cancer research, suggesting that alterations in lipid metabolism are closely linked to cancer development. However, the causal relationship between specific lipid profiles and digestive system cancer risk remains unclear.
METHODS: Using a two-sample Mendelian randomization (MR) approach, we elucidated the causal relationships between lipidomic profiles and the risk of five types of digestive system cancer: stomach, liver, esophageal, pancreatic, and colorectal cancers. The aim of this study was to investigate the effect impact of developing lipid profiles on the risk of digestive system cancers utilizing data from public databases such as the GWAS Catalog and the UK Biobank. The inverse‒variance weighted (IVW) method and other strict MR methods were used to evaluate the potential causal links. In addition, we performed sensitivity analyses and reverse MR analyses to ensure the robustness of the results.
RESULTS: Significant causal relationships were identified between certain lipidomic traits and the risk of developing digestive system cancers. Elevated sphingomyelin (d40:1) levels were associated with a reduced risk of developing gastric cancer (odds ratio (OR) = 0.68, P < 0.001), while elevated levels of phosphatidylcholine (16:1_20:4) increased the risk of developing esophageal cancer (OR = 1.31, P = 0.02). Conversely, phosphatidylcholine (18:2_0:0) had a protective effect against colorectal cancer (OR = 0.86, P = 0.036). The bidirectional analysis did not suggest reverse causality between cancer risk and lipid levels. Strict MR methods demonstrated the robustness of the above causal relationships.
CONCLUSION: Our findings underscore the significant causal relationships between specific lipidomic traits and the risk of developing various digestive system cancers, highlighting the potential of lipid profiles in informing cancer prevention and treatment strategies. These results reinforce the value of MR in unraveling complex lipid-cancer interactions, offering new avenues for research and clinical application.
Temporomandibular dysfunction (TMD) is a musculoskeletal and neuromuscular system-related condition that affects the masticatory muscles, temporomandibular joint, and other related structures. Psychological factors are stated as comorbid in individuals with TMD. Individuals with TMD-related pain show higher levels of stress, anxiety, depression, somatic awareness, pain catastrophizing, and kinesiophobia compared to controls. Therefore, recent research has focused on pain catastrophe, kinesiophobia, and central sensitization, especially in individuals with TMD. Therefore, the aim of this study is to examine the relationship between pain, central sensitization, kinesiophobia and stress level in individuals with temporomandibular dysfunction. Ninety patients aged 18-65 years, who have TME-related complaints for at least 3 months, and diagnosed with TMD as a result of clinical and radiological evaluation by a dentist will be included in the study.
Disclosed are biomolecular complexes that are useful in the labelling of proteins with metal tricarbonyl groups. The biomolecular complex include a protein of interest and a labelling sequence capable of conjugation to a metal tricarbonyl ([M(CO) 3 ] + ). The labelling sequence consists of between 6 and 15 amino acid residues, of which between 4 and 6 are histidine residues and of which at least 2 residues are selected from the group consisting of lysine and/or arginine residues. The labelling sequence has an isoelectric point (pI) of at least 9. The biomolecular complexes of the invention are useful in molecular imaging, diagnostic and therapeutic applications. Also disclosed are nucleic acid molecules encoding such biomolecular complexes, methods of producing such biomolecular complexes; biomolecular complexes for use as medicaments in radiotherapy; and methods of treatment, diagnosis and molecular imaging utilising such molecular complexes.
The present invention relates to an external sterilizing Mongolian medicine lotion for skin and external genital organs, which is an external sterilizing Mongolian medicine lotion for preventing and treating the common infection of skin mucosae, male genital organs and female genital organs. The external sterilizing Mongolian medicine lotion is characterized in that the external sterilizing Mongolian medicine lotion is composed of the following synergy Chinese herbal medicines of foxtail-like sophora herb and seed, myrobalan, lotus seed, common cnidium fruit, alum, pearl and borneol. The preparing method comprises the steps that the water of which the quantity is ten times more than that of the medicine is added, and the external sterilizing Mongolian medicine lotion is formed by filtering dregs and extracting juice after the medicine and the water are decocted. The common using method comprises that after the external sterilizing Mongolian medicine lotion is diluted by the water by the ratio of 5%, the sick part is immersed or scrubbed for a certain time, and the sick part can be cured by one-time application every day. The present invention has the main advantages of high curing rate, low money consumption, strong pertinence, no toxic or side effect, and random use at home, and can be used as regular family health care medicine. The purpose of prevention can be obtained by scrubbing the part at irregular time.
A ketogenic diet can induce ketosis after a period of 2-3 days and offer the brain an alternative energy substrate to glucose in the form of ketone bodies. Feeding the brain ketone bodies can potentially benefit a stroke patient's brain in several ways:

Stroke is characterized by impaired blood and oxygen supply to brain cells. This can cause glucose to convert to lactate which is toxic for the brain. Decreasing glucose availability to brain cells may thus potentially decrease the area of damage in the ischemic penumbra (perifephery of the stroke). Compared with sugar, burning ketone bodies requires less oxygen to produce the same amount of energy, suggesting that brain cells could have a potential greater chance of surviving during circumstances of reduced oxygen supply. By decreasing mitochondria activity, ROS synthesis is also decreased, which can help decrease the necrotic area around the ischemic penumbra. Furthermore, the ketogenic diet does not induce an increase in blood sugar which could be an advantage since many stroke patients are admitted with hyperglycemia associated with a worse outcome.
A protease for activating the blood clotting factor VII and its proenzyme is described. Moreover, a process for obtaining the protease and its use in hemorrhage prophylaxis or hemostasis is described. A stabilized factor V and a stabilized factor VIII preparation are furthermore described which are free of the inactive factor VIII fragments formed by proteolytic degradation as a result of the inhibition or the removal of the protease activating the blood clotting factor VII. Moreover, a test system for the qualitative and quantitative detection of a protease which activates the blood clotting factor VII is described. Finally, pharmaceutical preparations are described which are suitable for the prophylaxis and treatment of bleeding events, e.g. in the presence of FVIII inhibitors, wound healing and for the treatment of disorders which are caused by fibrin-containing thrombin. The preparations contain the protease activating the blood clotting factor 'VII, or its proenzyme.
FIELD: medicine, ophthalmology. SUBSTANCE: invention proposes an agent for intraoperative and temporal postoperative tamponade of retina. Agent is the highly pure perfluoropolyester 6MF-130 of the general formula:  . Invention ensures to enhance tolerance of eye structures, decrease relapse incidence of detached retina and simplify intraocular manipulations. EFFECT: enhanced effectiveness of agent, decreased incidence of iatrogenic complications, decreased operation time. 2 tbl
This trial targeted to analyze the effects of different doses of tirofiban combined with dual antiplatelet drugs on platelet indices, vascular endothelial function, and major adverse cardiovascular events (MACE) in patients with acute ST-segment elevated myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI). A total of 180 patients with STEMI who underwent PCI were divided into Group A, Group B, and Group C (60 cases per group). Group A was given conventional medication, and Groups B and C were given a standard dose (10 μg/kg) and a high dose (20 μg/kg) of tirofiban on the basis of Group A, respectively. Thrombolysis in myocardial infarction (TIMI) myocardial perfusion grade and TIMI blood flow grade were compared. Myocardial enzymes, platelet indices, vascular endothelial function, inflammatory factors, and cardiac function indices were detected. In-hospital bleeding events and follow-up MACE were recorded. After PCI, Group C had a higher number of TIMI myocardial perfusion grade III and TIMI blood flow grade III versus Group A. Group C achieved the greatest changes in myocardial enzymes, platelet indices, vascular endothelial function-related factors, inflammatory factors, and cardiac function indices, followed by Group B and Group A. The incidence of bleeding events was higher in Group C than in Group A, and that of MACE in Group C was lower than in Group A. The addition of high-dose tirofiban to PCI and dual antiplatelet drugs for STEMI patients can improve myocardial blood perfusion, cardiac function, and vascular endothelial function, inhibit platelet activation and aggregation, and reduce the occurrence of MACE.
PURPOSE: To obtain a bath medicine composition which is effective for amelioration of systemic dry skin. CONSTITUTION: Herbs or their extracts for warming body is contained in an amount of 0.01-100ppm, calculated as the essence. Further, urea and vitamin A are formulated to the bath medicine composition in an amounts of 0.1-500 and 0.01-100ppm based on the bath water, respectively. The body-warming herbs have the action to warm bodies and keep bodies warm by taking bath and selected from the group of Caryophylli Flos, Evodiae Fructus, Calami Rhizoma, Menthae Herba, Atractylodis Rhizoma, Carthami Flos, Capsici Fructus, rice plant, Aurantii pericarpium, Aurantii Nobilis Pericarpium, MATSUFUJI (Schisandra repanda Radlk), YUZU (citron), Juniperus communis, Cnidii Rhizoma, german chamomile, camphor, Schizonepetae Herba, sage, Magnoliae Cortex, Cinnamoni cortex, Glychyrrhizae Radix, Atractylodis Lanceae Rhizoma, Angelica Radix.  Vitamin A is selected from retinol, retinol acetate, retinol palmitate, dehydroretinol and vitamin A oil, retinoic acid and β-carotin. Systemic administration of urea and vitamin A becomes possible and the itching unique to post- bathing can be inhibited.